Results

1–10 of 17 results for VEGF-A

Faricimab Rapidly Improves Fluid Parameters in Patients With nAMD
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2023
Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2023
Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for Up to 16 Weeks in nAMD and DME
Rajeev H. Muni, MD, MSC, FRCS(C), FASRS
Annual Meeting Talks
2023
Impact of Faricimab vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials
Glenn J. Jaffe, MD
Annual Meeting Talks
2023
Preclinical Analysis of a Novel Trispecific Antibody, RO-104, for Use in Retinal Neovascular Disease
Subhransu K. Ray, MD, PhD
Annual Meeting Talks
2024
Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
Angiopoietin-2 Signaling and Vascular Stability With Faricimab in Diabetic Macular Edema
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2022
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2022
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2022